key: cord-0749705-udr78zwr authors: McAdams, Meredith C.; Xu, Pin; Saleh, Sameh N.; Li, Michael; Ostrosky-Frid, Mauricio; Gregg, L. Parker; Willett, Duwayne L.; Velasco, Ferdinand; Lehmann, Christoph U.; Hedayati, S. Susan title: Risk Prediction for Acute Kidney Injury in Patients Hospitalized With COVID-19 date: 2022-04-08 journal: Kidney Med DOI: 10.1016/j.xkme.2022.100463 sha: 2350d1e035cf61254079e92e489d3e36b5c92912 doc_id: 749705 cord_uid: udr78zwr RATIONALE & OBJECTIVE: Acute kidney injury (AKI) is common in patients hospitalized with COVID-19, but validated, predictive models for AKI are lacking. We aimed to develop the best predictive model for AKI in hospitalized patients with COVID-19 and assess its performance over time with the emergence of vaccines and the delta variant. STUDY DESIGN: Longitudinal cohort study. SETTING & PARTICIPANTS: Hospitalized patients with a positive SARS CoV-2 PCR between 3/1/2020 and 8/20/2021 at 19 Texas hospitals. EXPOSURES: Comorbidities, baseline laboratory data, inflammatory biomarkers. OUTCOMES: AKI defined by KDIGO creatinine criteria ANALYTICAL APPROACH: Three nested models for AKI were built in a development cohort and validated in two out-of-time cohorts. Model discrimination and calibration measures were compared among cohorts to assess performance over time. RESULTS: Of 10,034 patients, 5,676, 2,917, and 1,441 were in the development, validation 1, and validation 2 cohorts, of whom 776 (13.7%), 368 (12.6%), and 179 (12.4%) developed AKI (P=0.33). Patients in validation 2 had fewer comorbidities and were younger than the development or validation 1 cohorts (mean age, 54±16.8 years vs. 61.4±17.5 and 61.7±17.3 years, respectively, P<0.001). Validation 2 had higher median hsCRP, 81.7 mg/L, vs. development cohort, 74.5 mg/L (P<0.01), and higher median ferritin, 696 ng/mL, vs. both development, 444 ng/mL, and validation 1, 496 ng/mL, (P<0.001). The final model, which added hsCRP, ferritin, and D-dimer, had AUC=0.781 (95% CI, 0.763, 0.799). Compared to the development cohort, discrimination by AUC (validation 1: 0.785 [0.760, 0.810], P=0.79, and validation 2: 0.754 [0.716, 0.795], P=0.47) and calibration by ECI (validation 1: 0.116 [0.041, 0.281], P=0.11, and validation 2: 0.081 [0.045, 0.295], P=0.11) showed stable performance over time. LIMITATIONS: Potential billing and coding bias. CONCLUSIONS: We developed and externally validated a model to accurately predict AKI in patients with COVID-19. Performance withstood changes in practice patterns and virus variants. The coronavirus disease 2019 (COVID-19) may have multi-organ involvement, and acute kidney injury (AKI) is a known sequela. Potential mechanisms include acute tubular injury because of hypotension, intravascular volume depletion leading to prerenal injury, and acute interstitial nephritis from antibiotics and antiviral treatments. However, COVID-specific mechanisms are also likely involved in kidney injury, as evidenced by case reports and post-mortem autopsies. 1, 2 Observational studies that controlled for typical AKI risk factors revealed that COVID-19 is associated with AKI, suggesting that part of the pathogenesis may be specific to the virus itself. 3 COVIDrelated mechanisms may include kidney ischemia from hypercoagulability, inflammation-related kidney injury in the setting of cytokine storm, and cardiorenal syndrome. 4 Older age, male sex, and a history of diabetes mellitus, chronic kidney disease (CKD), and hypertension are associated with AKI in patients with COVID-19. [5] [6] [7] [8] [9] [10] However, predictive models with temporal external validation to prognosticate the development of AKI in the setting of hospitalization for COVID-19 are lacking. This is especially pertinent given the evolution of the pandemic over time due to changes in clinical management, vaccination, and emergence of new variants. With the rollout of COVID-19 vaccines, cases began to decline in late 2020 and early 2021. However, the emergence of the delta variant in March 2021 led to a subsequent rebound in cases. Delta soon became the dominant variant, with 70% of U.S. COVID-19 cases attributable to the delta variant by July 1, 2021 and 98% by August 1, 2021. 11 The U.S. saw a rapid rise in hospitalizations due to a marked increase in J o u r n a l P r e -p r o o f transmissibility and number of breakthrough infections with the delta variant compared to the original strains. 12, 13 Increasing evidence suggests that infection with the delta variant leads to more severe illness in unvaccinated individuals [13] [14] [15] and an increased risk of hospitalization when compared to previously prominent variants. 16, 17 It is unclear, however, what effect the delta variant has on AKI pathogenesis, incidence, and outcomes. We, therefore, aimed to (1) derive a prognostic model to predict the risk of AKI using granular demographic, clinical, and laboratory variables, including inflammatory biomarkers, during an index hospitalization with COVID-19; (2) externally evaluate the model predictive performance based on discrimination and calibration with out-of-time cohorts; and 3) assess data shifts in the pandemic due to varying treatments and emergence of the delta variant. We conducted a longitudinal study utilizing the University of Texas Southwestern (UTSW) COVID- 19 Registry Collaborative database that contains granular demographic, clinical, and laboratory data on all COVID-19-related hospital admissions at 19 hospitals in North Texas, including UTSW Clements University Hospital and 18 hospitals in the Texas Health Resources Health System. Ethics approval and written informed consent were not required as the research was declared exempt by the Institutional Review Board at UTSW as non-human research using existing data from the COVID-19 registry. For the development cohort, we included all individuals ≥18 years of age with a positive SARS-CoV2 polymerase chain reaction (PCR) test admitted between 3/1/2020 and 1/1/2021. The first hospital admission after the first positive PCR or up to 10 days prior J o u r n a l P r e -p r o o f was used. Only the first hospital admission was used if an individual had multiple admissions within the timeframe. We excluded patients 1) admitted for observation, 2) without a COVID-19-associated billing diagnosis, 3) with End Stage Kidney Disease (ESKD) or kidney transplantation, 4) without comorbidity information or a measured serum creatinine during hospitalization, or 5) AKI already present on admission ( Figure S1 ). Data were collected for the whole hospitalization or a minimum of 30 days. Two out-of-time validation cohorts were used. Validation 1 cohort included patients with a positive SARS-CoV2 PCR admitted between 1/2/2021 and 6/30/2021, while Validation 2 cohort included those admitted between 7/1/2021 and 8/20/2021. The same exclusion criteria were applied for the validation cohorts. July and August 2021 were grouped together as the COVID-19 delta variant was the predominant strain at both UTSW and in Texas at-large based on variant testing 18 . Demographic variables, past medical history, and medications prior to admission were extracted from the Electronic Health Record (EHR) (Epic Systems, Verona, WI). We collected treatments during hospitalization, including medications and mechanical ventilation, intensive care unit (ICU) utilization, and kidney replacement therapy (KRT). We obtained laboratory variables at admission and during hospitalization. Comorbidities were considered present if the condition was listed as Active on the patient's Problem List, Medical History, or Hospital Problem and/or used 2 or more times (to improve specificity) as an Encounter or Billing Diagnosis. Computable condition definitions were expressed as intentional (rule-based) value sets defined using standard SNOMED CT nomenclature as previously described (where 125 condition definitions are included as an J o u r n a l P r e -p r o o f online Supplement to this reference) 19 . Computable definitions of laboratory variables and inflammatory biomarkers were expressed using an internally-vetted value set field within the Epic EHR. This field ("Common Name") is used to determine which laboratory results can be displayed together for clinical viewing within the EHR to meet pathology and laboratory accreditation requirements. A detailed pre-specified algorithm was used to define AKI according to standard Figure S2 ). 20 Urine output criteria were not used given variability in documentation. Patients were stratified according to the highest AKI stage attained during hospitalization. AKI was categorized as present on admission if admission creatinine was higher than baseline creatinine and met one of the AKI stage criteria. We defined "baseline creatinine" by adapting and modifying a published algorithm, based on availability or absence of prior serum creatinine values ( Figure S3 ). 8 J o u r n a l P r e -p r o o f The pre-specified primary outcome was in-hospital development of AKI that was not present on admission. Categorical data were presented as percentages and continuous data as means ± standard deviation (SD) were compared with likelihood ratio tests after adding each biomarker group. A separate missing category for categorical variables was created, and complete case analysis was used for modeling. The estimated effect was reported by adjusted odds ratios (ORs) with their 95% confidence intervals (95% CIs). We assessed the models for multicollinearity using variance inflation factors (VIF), where a VIF greater than ten suggested multicollinearity. 21 No multicollinearity was found by VIF analysis. A mathematic model was derived to compute the log odds (logit) of AKI that could be transformed to predict the probability of AKI. The variable importance was assessed by the absolute value of the t-statistic for each variable in the models. 22 The performance of prognostic models was internally validated by 10-fold The development, validation 1, and validation 2 cohorts contained 5,676 individuals, 2,917 individuals, and 1,441 individuals, respectively. Demographics, comorbidities, laboratory values, and clinical outcomes of the three cohorts are shown in Outcomes of the three cohorts are illustrated in Table 1 . Outcomes of the development cohort grouped by presence and stage of AKI can be seen in Table S1 . There were 776 (13.7%) patients in the development cohort, 368 (12.6%) in validation cohort 1, and 179 (12.4%) in validation cohort 2 who developed AKI. There was no difference in AKI rates among the cohorts. The rates of mechanical ventilation, inhospital mortality, and KRT were also similar among the three cohorts. The rate of ICU admission was significantly higher in the development cohort when compared to validation cohort 1 (adjusted P<0.001). Age, hypertension, and ferritin level were found to show a small change over time in validation cohort 2 (0.10